Biomarkers support lung cancer diagnosis, treatment

Early diagnosis of lung cancer is important for its treatment, but it's not always easy because many diseases start with similar symptoms, such as a simple cough, and more in-depth investigations are invasive, costly or inaccurate. Screening using fluid from the lining of the lung would be quicker, less invasive and lower-cost, and researchers have found a biomarker that could make this earlier diagnosis much more practical.

In a study published in the Journal of Thoracic Oncology, researchers looked at a specific type of fluid in the lung, the endobronchial epithelial-lining fluid (ELF), taken from near lung nodules spotted on CT scans. They found that expression of the TNC (tenasin-C) gene and the size of the nodule could predict lung cancer.

Genetic biomarkers could also improve treatment outcomes. In 2006, researchers from the University of North Carolina reported that lung cancers can be divided into three subtypes. In a new study, published in PLoS One, they found that these subtypes and the genetic changes in the tumors can affect how people respond to treatment.

This confirms that lung cancer is a complex disease and that these subtypes and genetic changes could be used to predict people's responses to different treatments, improving outcomes for patients and potentially speeding up drug development as well.

- read the press release about the lung lining marker
- see the abstract from the Journal of Thoracic Oncology
- check out the press release about cancer subtypes
- see the abstract from PLoS One

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.